| Name | Title | Contact Details |
|---|---|---|
Bill Jacoby |
Supply Chain Manager | Profile |
Rebecca Timmons |
Chief Product Officer | Profile |
Liam Rooney |
Deputy CFO, Alltech | Profile |
Flora Djojo |
Deputy Chief Financial Officer | Profile |
Christopher Speight |
Chief Financial Officer | Profile |
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III
Connecticut Chiropractic Association is a Rocky Hill, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Otsuka America is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Accubill Medical Services, LLC is a Waterford, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
SoftScript is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.